On January 19, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) disclosed the draft employee stock ownership plan for 2022, which plans to sell more than 3 million shares at a current price of about 350 yuan per share to employees at a price of 50 yuan per share, which is jokingly called the new “fancy year-end”.
With the news, the company’s share price soared by nearly 6% on the 20th. Before that, the company’s share price fell continuously because there were rumors that the company’s performance did not meet the standard and a large number of salespeople left.
Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) offering “fancy year-end”?
3 million shares sold to employees
On January 19, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) disclosed the employee stock ownership plan (Draft) for 2022. The participants are the core employees and technical backbone of the company. The total number of participants in this stock ownership plan does not exceed 2700, and the total capital does not exceed 150 million yuan.
\u3000\u3000
according to the company’s announcement
It is reported that the share source of the employee stock ownership plan is the shares repurchased by the company’s special account for repurchase, with a total of no more than 3.0487 million shares, accounting for about 0.2508% of the current total share capital of the company.
More attention is paid to the subscription price of the employee stock ownership plan, which is 50 yuan / share. As of the closing on January 20, the latest share price of Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) was 354.94 yuan / share, based on this calculation, it is equivalent to selling the company’s shares to employees at a discount of 1.40.
The news soon aroused heated discussion among stock bar investors . Some people praised the company for buying back shares at its own expense, and the employees were “smart”, while others were worried about whether the shares issued to employees were from all shareholders? Will the investors “suffer losses”?
During the period of , investors were curious. Is this another kind of “fancy year-end” of listed companies?
Similar doubts are not unreasonable. Some analysts pointed out that the employees participating in this share holding plan do not involve the company’s directors, supervisors and senior managers. At the same time, the number of employees up to 2700 also accounts for 23% of the total number of employees in 2020. Although it is not for all employees, the incentive scope is still wide, which can be regarded as the “year-end benefits” for core backbone employees.
“yaoximao” frequently sends negative
the share price fell sharply several times before
it is worth noting that at the beginning of this month, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) spread negative rumors such as the company’s performance falling short of expectations and a large number of salespeople leaving their jobs, and the stock price once fell continuously.
In response, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) responded that the company has not disclosed the 2021 annual report, so it is unable to disclose information related to performance. However, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) has not released any news affecting the performance trend, nor has there been any event that the performance did not meet expectations and the salesperson resigned.
in this context, the employee stock ownership plan is also interpreted as “golden handcuffs” by some views, locking key employees through the “fancy year-end” of real gold and silver.
According to the announcement, the duration of the employee stock ownership plan is 48 months, calculated from the date when the company announces the last transfer of the subject stock to the name of the employee stock ownership plan. The subject shares obtained by the employee stock ownership plan are unlocked in three phases. The unlocking time points are 12 months, 24 months and 36 months respectively from the date when the company announces the last transfer of the subject shares to the name of the employee stock ownership plan, and the maximum locking period is 36 months.
At the same time, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) also set performance growth assessment objectives. Between 2022 and 2024, the company’s annual net profit needs to increase by 20%. If the company fails to meet the corresponding unlocking conditions, the locking period of all incentive objects’ shares that can be unlocked in the current year will be extended.
According to the data, Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) is mainly engaged in the R & D, manufacturing, marketing and service of medical devices, and is committed to providing high-quality products and services for global medical institutions. Since its listing in 2018, the net profit of the company’s revenue has never been less than 20%. Coupled with the explosive covid-19 detection hot spot concept, the company was previously known as “yaozhimao” in a shares.
after the announcement of the employee stock ownership plan, a large number of “optimistic” research reports of securities companies were also intensively released overnight, pointing out that this is a major event that has a great impact on the company’s stock price.
However, the recent sharp falls of “yaoximao” are not without reasons.
For example, in the “storm of centralized procurement” exposed last year, although the company responded that the current centralized procurement promoted by the national medical insurance administration is mainly in the field of drugs and high-value consumables, and the products of the company’s three business areas do not involve drugs and high-value consumables, so “it has no impact on the company’s business base”… However, in the third quarter of 2021, the company’s share price still fell by more than 40%.
In the view of many institutions, the company still has a number of risks, such as new product research and development is not as expected, overseas sales are not as expected and exchange rate risk, supply chain risk, centralized purchase price reduction is higher than expected, M & A integration is lower than expected, etc.
